These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16336251)

  • 1. Co-activator and co-repressor interplay on the human androgen receptor.
    Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
    Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
    [No Abstract]   [Full Text] [Related]  

  • 2. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
    Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
    Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
    Karvonen U; Jänne OA; Palvimo JJ
    FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific recognition of androgens by their nuclear receptor. A structure-function study.
    Poujol N; Wurtz JM; Tahiri B; Lumbroso S; Nicolas JC; Moras D; Sultan C
    J Biol Chem; 2000 Aug; 275(31):24022-31. PubMed ID: 10787411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
    Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
    Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    Berrevoets CA; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
    Kemppainen JA; Wilson EM
    Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
    [No Abstract]   [Full Text] [Related]  

  • 8. Ligand-specific dynamics of the androgen receptor at its response element in living cells.
    Klokk TI; Kurys P; Elbi C; Nagaich AK; Hendarwanto A; Slagsvold T; Chang CY; Hager GL; Saatcioglu F
    Mol Cell Biol; 2007 Mar; 27(5):1823-43. PubMed ID: 17189428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circumventing anti-androgen resistance by molecular design.
    McGinley PL; Koh JT
    J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
    Furr BJ
    Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgens and pharmacology.
    Haendler B
    Andrologia; 2005 Dec; 37(6):213-5. PubMed ID: 16336252
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
    van de Wijngaart DJ; Molier M; Lusher SJ; Hersmus R; Jenster G; Trapman J; Dubbink HJ
    J Biol Chem; 2010 Feb; 285(7):5097-105. PubMed ID: 20007693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
    Miyamoto H; Yeh S; Wilding G; Chang C
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiandrogens. Mechanisms and paradoxical effects].
    Mowszowicz I
    Ann Endocrinol (Paris); 1989; 50(3):189-99. PubMed ID: 2530930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.